Vivek Verma1, Taylor R Cushman2, Ugur Selek3, Chad Tang2, James W Welsh4. 1. Department of Radiation Oncology, Allegheny General Hospital, Pittsburgh, Pennsylvania. 2. Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas. 3. Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas; Department of Radiation Oncology, School of Medicine, Koc University, Istanbul, Turkey. 4. Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas. Electronic address: jwelsh@mdanderson.org.
Abstract
PURPOSE: The safety of combined immunotherapy and thoracic radiation therapy (iRT) has been understudied. We evaluated toxicities in patients receiving iRT from 3 single-institutional phase 1/2 trials. METHODS AND MATERIALS: Clinical/treatment characteristics and toxicities (per the Common Toxicity Criteria for Adverse Events, version 4.0) were extracted. For purposes of this analysis, groupings were made into (1) patients receiving immunotherapy plus stereotactic body radiation therapy (50 Gy/4 fractions or 60 Gy/10 fractions), (2) immunotherapy plus 45 Gy/15 fractions, and (3) twice-daily chemoimmunoradiotherapy (45 Gy in twice-daily fractions). RESULTS: None of the 60 patients undergoingimmunotherapy plus stereotactic body radiation therapy (50 Gy, n = 49; 60 Gy, n = 11) experienced grade ≥4 events. There were 34 instances of any grade 3 event (in 15 total patients), with 9 pulmonary specific grade 3 events (in 4 patients). In the patients receiving 45 Gy/15 fractions (small cell lung cancers, n = 26; non-small cell lung cancers, n = 27), there were 2 grade 4 events (in the same patient), along with 17 grade 3 toxicities experienced by 10 total patients (2 pulmonary specific). Lastly, in the twice-daily cohort (n = 22), there were 5 grade 4 events (3 of which occurred in 1 patient) and 16 grade 3 toxicities occurring in 8 total patients (half of which were hematologic). CONCLUSIONS: Administration of combined iRT is safe in the short term. Toxicities did not appreciably associate with demographics or dosimetry.
RCT Entities:
PURPOSE: The safety of combined immunotherapy and thoracic radiation therapy (iRT) has been understudied. We evaluated toxicities in patients receiving iRT from 3 single-institutional phase 1/2 trials. METHODS AND MATERIALS: Clinical/treatment characteristics and toxicities (per the Common Toxicity Criteria for Adverse Events, version 4.0) were extracted. For purposes of this analysis, groupings were made into (1) patients receiving immunotherapy plus stereotactic body radiation therapy (50 Gy/4 fractions or 60 Gy/10 fractions), (2) immunotherapy plus 45 Gy/15 fractions, and (3) twice-daily chemoimmunoradiotherapy (45 Gy in twice-daily fractions). RESULTS: None of the 60 patients undergoing immunotherapy plus stereotactic body radiation therapy (50 Gy, n = 49; 60 Gy, n = 11) experienced grade ≥4 events. There were 34 instances of any grade 3 event (in 15 total patients), with 9 pulmonary specific grade 3 events (in 4 patients). In the patients receiving 45 Gy/15 fractions (small cell lung cancers, n = 26; non-small cell lung cancers, n = 27), there were 2 grade 4 events (in the same patient), along with 17 grade 3 toxicities experienced by 10 total patients (2 pulmonary specific). Lastly, in the twice-daily cohort (n = 22), there were 5 grade 4 events (3 of which occurred in 1 patient) and 16 grade 3 toxicities occurring in 8 total patients (half of which were hematologic). CONCLUSIONS: Administration of combined iRT is safe in the short term. Toxicities did not appreciably associate with demographics or dosimetry.
Authors: Sibo Tian; Jeffrey M Switchenko; Zachary S Buchwald; Pretesh R Patel; Joseph W Shelton; Shannon E Kahn; Rathi N Pillai; Conor E Steuer; Taofeek K Owonikoko; Madhusmita Behera; Walter J Curran; Kristin A Higgins Journal: Int J Radiat Oncol Biol Phys Date: 2020-01-24 Impact factor: 7.038
Authors: James W Welsh; Chad Tang; Patricia de Groot; Aung Naing; Kenneth R Hess; John V Heymach; Vassiliki A Papadimitrakopoulou; Taylor R Cushman; Vivek Subbiah; Joe Y Chang; George R Simon; Rishab Ramapriyan; Hampartsoum B Barsoumian; Hari Menon; Maria Angelica Cortez; Erminia Massarelli; Quynh Nguyen; Padmanee Sharma; James P Allison; Adi Diab; Vivek Verma; Uma Raju; Sherif G Shaaban; Ramona Dadu; Maria E Cabanillas; Kelvin Wang; Clark Anderson; Daniel R Gomez; Stephen Hahn; Ritsuko Komaki; David S Hong Journal: Cancer Immunol Res Date: 2019-10-28 Impact factor: 11.151
Authors: Rodolfo Chicas-Sett; Ignacio Morales-Orue; Juan Castilla-Martinez; Juan Zafra-Martin; Andrea Kannemann; Jesus Blanco; Marta Lloret; Pedro C Lara Journal: Int J Mol Sci Date: 2019-05-02 Impact factor: 5.923
Authors: Hari Menon; Rishab Ramapriyan; Taylor R Cushman; Vivek Verma; Hans H Kim; Jonathan E Schoenhals; Cemre Atalar; Ugur Selek; Stephen G Chun; Joe Y Chang; Hampartsoum B Barsoumian; Quynh-Nhu Nguyen; Mehmet Altan; Maria A Cortez; Stephen M Hahn; James W Welsh Journal: Front Immunol Date: 2019-02-15 Impact factor: 7.561
Authors: May Elbanna; Kevin Shiue; Donna Edwards; Alberto Cerra-Franco; Namita Agrawal; Jason Hinton; Todd Mereniuk; Christina Huang; Joshua L Ryan; Jessica Smith; Vasantha D Aaron; Heather Burney; Yong Zang; Jordan Holmes; Mark Langer; Richard Zellars; Tim Lautenschlaeger Journal: Clin Lung Cancer Date: 2020-06-02 Impact factor: 4.785